What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Cancer
His primary areas of study are Internal medicine, Waldenstrom macroglobulinemia, Cancer research, Macroglobulinemia and Immunology.
The study incorporates disciplines such as Gastroenterology, Endocrinology, Surgery and Oncology in addition to Internal medicine.
His research in Waldenstrom macroglobulinemia intersects with topics in Monoclonal gammopathy of undetermined significance, Mutation, Bortezomib, Immunoglobulin M and Immunopathology.
His Cancer research research is multidisciplinary, relying on both Cell culture, Apoptosis, Signal transduction, Cell killing and Bone marrow.
His Macroglobulinemia research includes themes of Lymphoplasmacytic Lymphoma, Nucleoside analogue, Ibrutinib, Bing–Neel syndrome and Lymphoma.
Within one scientific family, Steven P. Treon focuses on topics pertaining to Frameshift mutation under Immunology, and may sometimes address concerns connected to Myelokathexis.
His most cited work include:
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (853 citations)
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (853 citations)
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (827 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Waldenstrom macroglobulinemia, Internal medicine, Macroglobulinemia, Cancer research and Immunology.
He has researched Waldenstrom macroglobulinemia in several fields, including Immunoglobulin M, Ibrutinib and CXCR4.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Surgery and Oncology.
His Macroglobulinemia research is multidisciplinary, incorporating elements of Molecular biology, Lymphoplasmacytic Lymphoma, CD19 and Pathology.
Steven P. Treon combines subjects such as Cell culture, Apoptosis, Signal transduction, Kinase and Bone marrow with his study of Cancer research.
His studies in Multiple myeloma, Antibody and Antigen are all subfields of Immunology research.
He most often published in these fields:
- Waldenstrom macroglobulinemia (45.32%)
- Internal medicine (41.81%)
- Macroglobulinemia (37.63%)
What were the highlights of his more recent work (between 2016-2021)?
- Waldenstrom macroglobulinemia (45.32%)
- Ibrutinib (18.23%)
- Internal medicine (41.81%)
In recent papers he was focusing on the following fields of study:
Steven P. Treon mainly focuses on Waldenstrom macroglobulinemia, Ibrutinib, Internal medicine, Cancer research and Oncology.
His Waldenstrom macroglobulinemia study integrates concerns from other disciplines, such as Previously treated, Immunoglobulin M, Bone marrow and CXCR4.
His study in Ibrutinib is interdisciplinary in nature, drawing from both Progressive disease, Discontinuation, Progression-free survival, Macroglobulinemia and Bruton's tyrosine kinase.
His Macroglobulinemia study is related to the wider topic of Multiple myeloma.
His work on Rituximab, Clinical trial and Bortezomib is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science.
His Cancer research study also includes
- Lymphoma that intertwine with fields like Pathological,
- breakpoint cluster region that intertwine with fields like Syk.
Between 2016 and 2021, his most popular works were:
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology (184 citations)
- A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader (137 citations)
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia (136 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
Steven P. Treon spends much of his time researching Ibrutinib, Internal medicine, Waldenstrom macroglobulinemia, CXCR4 and Oncology.
The various areas that he examines in his Ibrutinib study include Cancer research, Pulmonary Injury, Mutation, Neutropenia and Bruton's tyrosine kinase.
His research integrates issues of Viability assay, Cell culture, Signal transduction, Lymphoma and In vivo in his study of Cancer research.
Lymphoma is a primary field of his research addressed under Immunology.
His Internal medicine study typically links adjacent topics like Gastroenterology.
His Waldenstrom macroglobulinemia research integrates issues from Clinical trial, Progression-free survival, Pathogenesis, Anemia and Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
